CD22 Antibody (HD6): sc-73362

CD22 Antibody (HD6) is a mouse monoclonal IgG1 antibody that detects CD22 in human samples through immunoprecipitation (IP), immunofluorescence (IF), and flow cytometry (FCM). CD22 is a critical regulator of B cell signaling and plays a vital role in the immune response by modulating B cell activation and proliferation. This integral membrane glycoprotein is primarily located on the surface of B lymphocytes, where CD22 functions as a cell adhesion molecule, facilitating interactions between B cells and other immune cells. CD22 expression on mature B cells is essential for maintaining immune tolerance and preventing autoimmunity, as anti-CD22 antibody (HD6) helps to regulate the strength and duration of B cell receptor signaling. Additionally, CD22 undergoes alternative splicing, resulting in two isoforms, CD22α and CD22β, with CD22β being the predominant form. CD22′s ability to form heterodimers with its isoforms enhances functional diversity, allowing for fine-tuned regulation of B cell responses. Anti-CD22 antibody (HD6) is an invaluable tool for researchers studying B cell biology and related diseases, including acute lymphocytic leukemia, where the cytoplasmic form of CD22 serves as a significant marker.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

CD22 Antibody (HD6) References:

1. Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents.  |  Newton, DL., et al. 2001. Crit Rev Oncol Hematol. 39: 79-86. PMID: 11418304
2. CD22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells.  |  Peng, W. and Paulson, JC. 2017. J Am Chem Soc. 139: 12450-12458. PMID: 28829594
3. CD22 Controls Germinal Center B Cell Receptor Signaling, Which Influences Plasma Cell and Memory B Cell Output.  |  Meyer, SJ., et al. 2021. J Immunol. 207: 1018-1032. PMID: 34330755
4. Human CD22-Transgenic, Primary Murine Lymphoma Challenges Immunotherapies in Organ-Specific Tumor Microenvironments.  |  Gsottberger, F., et al. 2021. Int J Mol Sci. 22: PMID: 34638774
5. Enhancement of Gene Knockdown on CD22-Expressing Cells by Chemically Modified Glycan Ligand-siRNA Conjugates.  |  Harumoto, T., et al. 2022. ACS Chem Biol. 17: 292-298. PMID: 35020348
6. Circulating CD22+/CD19-/CD24- progenitors and CD22+/CD19+/CD24- mature B cells: Diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia.  |  Zhou, T., et al. 2023. Cytometry B Clin Cytom. 104: 294-303. PMID: 36433814
7. Deciphering prognostic value of CD22 and its contribution to suppression of proinflammatory cytokines production in patients with IgA nephropathy.  |  Liu, Y., et al. 2023. Immunol Lett. 255: 40-46. PMID: 36848961
8. Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies.  |  Chen, J., et al. 2023. Heliyon. 9: e17960. PMID: 37456045
9. Dual targeting of CD19 and CD22 against B-ALL using a novel high-sensitivity aCD22 CAR.  |  Kokalaki, E., et al. 2024. Mol Ther. 32: 556-558. PMID: 38103549
10. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor.  |  Sato, S., et al. 1998. Semin Immunol. 10: 287-97. PMID: 9695185

The preferred CD22 antibody is CD22 Antibody (D-5): sc-271579.